Liyun Li

Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study

Sung-Bae Kim, J. Ajani, E. Van Cutsem, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

RATIONALE 311: tislelizumab plus concurrent chemoradiotherapy for localized esophageal squamous cell carcinoma.

Weihu Wang, K. Zhao, R. Yu, 2021, Future oncology.

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.

E. Van Cutsem, E. Raymond, R. Ishihara, 2023, The Lancet. Oncology.

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

Sung-Bae Kim, J. Ajani, C. Borg, 2021 .

Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial

L. Wyrwicz, S. Rha, L. Fornaro, 2024, BMJ.